Plus   Neg

Stock Alert: Phio Pharmaceuticals Shares Up 9%

Phio Pharmaceuticals Corp. (PHIO) shares are rising over 9% today, after the company announced data from various animal studies validating the potential of Phio's INTASYL technology as a cancer immunotherapy platform for developing novel compounds.

The company noted that the preclinical findings, which would be presented in further detail at upcoming scientific conferences, demonstrate that the INTASYL-enabled compounds can effectively be used to reduce immunosuppression in the tumor microenvironment (TME), which is one of the key challenges for many other immunotherapy platforms to achieve an adequate therapeutic effect in solid tumors.

Phio stated that its scientists conducted several animal studies with a mouse version of PH-762 (mPH-762) and with PH-894 in a validated mouse model of cancer (murine hepatocellular carcinoma model with Hepa1-6 cells). These studies show that a local administration of mPH-762 or PH-894 through intra-tumoral injection resulted in potent anti-tumoral effects. The treated animals showed a complete and statistically significant inhibition of tumor growth, whereas placebo treated animals displayed exponential tumor growth, thecompany added.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT